115 related articles for article (PubMed ID: 7957332)
1. Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin.
Deppe G; Malviya VK; Malone JM; Christensen CW; Saunders D
Eur J Gynaecol Oncol; 1994; 15(4):263-6. PubMed ID: 7957332
[TBL] [Abstract][Full Text] [Related]
2. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W;
J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299
[TBL] [Abstract][Full Text] [Related]
4. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
[TBL] [Abstract][Full Text] [Related]
6. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.
Long HJ; Nelimark RA; Podratz KC; Suman V; Keeney GL; Nikcevich DA; Kugler JW; Rowland KM; Kardinal CG; Wos EJ
Gynecol Oncol; 2006 Mar; 100(3):501-5. PubMed ID: 16185755
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma.
Long HJ; Langdon RM; Cha SS; Veeder MH; Pfeifle DM; Krook JE; Ebbert LP; Tschetter LK; Roshon SG
Gynecol Oncol; 1995 Aug; 58(2):240-3. PubMed ID: 7622111
[TBL] [Abstract][Full Text] [Related]
8. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group.
Barrett RJ; Blessing JA; Homesley HD; Twiggs L; Webster KD
Am J Clin Oncol; 1993 Dec; 16(6):494-6. PubMed ID: 8256764
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma.
Langer CJ; Catalano R; Weiner LM; Scher R; Bagchi P; Saren B; Comis RL
Cancer Invest; 1995; 13(2):150-9. PubMed ID: 7874568
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
Pierga JY; Diéras V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
Gynecol Oncol; 1997 Aug; 66(2):246-9. PubMed ID: 9264570
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma.
Smith MR; Peters WA; Drescher CW
Am J Obstet Gynecol; 1994 Jun; 170(6):1677-81; discussion 1681-2. PubMed ID: 8203425
[TBL] [Abstract][Full Text] [Related]
12. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
14. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
[TBL] [Abstract][Full Text] [Related]
15. Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Iop A; Cartei G; Vigevani E; Clocchiatti L; Mansutti M; Sibau AM
Am J Clin Oncol; 1997 Oct; 20(5):515-8. PubMed ID: 9345340
[TBL] [Abstract][Full Text] [Related]
16. Filgrastim support during combination chemotherapy using cisplatin, doxorubicin, and cyclophosphamide to treat advanced or recurrent endometrial cancer: a clinical study and literature review.
Hall DJ; Martin DA; Kincaid K
Eur J Gynaecol Oncol; 2003; 24(6):481-9. PubMed ID: 14658586
[TBL] [Abstract][Full Text] [Related]
17. [Combination chemotherapy using cyclophosphamide, adriamycin, and cisplatin in recurrent or advanced endometrial cancer--a preliminary report].
Baba S; Kashimura M; Shinohara M; Kusano S; Sasayama T; Hamasaki K
Gan No Rinsho; 1989 Feb; 35(3):371-7. PubMed ID: 2926985
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of carboplatin and cisplatin in advanced ovarian cancer.
Segelov E; Stuart-Harris R; Bell D; Tattersall M; Hutton-Potts J; Friedlander M
Eur J Gynaecol Oncol; 1994; 15(4):277-82. PubMed ID: 7957335
[TBL] [Abstract][Full Text] [Related]
19. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
20. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.
Modesitt SC; Tian C; Kryscio R; Thigpen JT; Randall ME; Gallion HH; Fleming GF;
Gynecol Oncol; 2007 Apr; 105(1):59-65. PubMed ID: 17150247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]